← Back to Treatments
🏅 FDA Orphan Designation

DANYELZA

naxitamab-gqgk

Manufacturer: Y-mAbs Therapeutics, Inc.

Indicated for:
NeuroblastomaOrphan

FDA-Approved Indications (1)

NeuroblastomaOrphan Designation

Treatment of pediatric patients 1 year of age and older with relapsed or refractory neuroblastoma with bone or bone marrow disease who have demonstrated partial response, minor response, mixed respons…

Indications & Usage

in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy

💙 Support Programs

View all →
DANYELZA
YmAbs
Copay card ↗Apply ↗
DANYELZA�
Y-mAbs Therapeutics, Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.